CreativeOne Wealth’s abrdn Life Sciences Investors HQL Stock Holding History

CreativeOne Wealth’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,012	Closed	-$229K	–	768
2021 Q3	$229K	Buy	11,012 +473	+4%	+$10.1K	0.01%	625
2021 Q2	$226K	Buy	+10,539	New	+$213K	0.01%	617

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AUB

Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

CreativeOne Wealth's HQL Position: Q4 2021 in Review

CreativeOne Wealth sold out of abrdn Life Sciences Investors (HQL) in Q4 2021, closing a stake of 11,012 shares — an estimated $229K sold.

CreativeOne Wealth first reported a position in HQL in Q2 2021 and held it in 2 quarters. The position peaked at $229K in Q3 2021. 67 funds tracked by Wall St. Rank hold HQL as of Q4 2021.

CreativeOne Wealth reported no remaining abrdn Life Sciences Investors position as of Q4 2021 after selling out during the quarter.
CreativeOne Wealth sold 11,012 abrdn Life Sciences Investors shares in Q4 2021, an estimated $229K.
CreativeOne Wealth first reported a position in abrdn Life Sciences Investors in Q2 2021 and held it in 2 quarters.
CreativeOne Wealth's abrdn Life Sciences Investors position peaked at $229K in Q3 2021.
67 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2021.

Based on CreativeOne Wealth's 13F filing for Q4 2021, filed 15 Feb 2022.